Incorporated in the State of Delaware on September 8, 2005, Raptor Pharmaceutical is the culmination of years of experience and research by a consortium of scientists, investors, and creative minds with one common goal, the development of novel protein therapeutics directed at unmet medical needs. On January 27, 2006, Raptor purchased intellectual property pertaining to the research and development of receptor-associated protein (RAP) technologies from BioMarin Pharmaceutical. Raptor is a biotechnology research and development company engaged in the development of drug and drug-targeting platforms based on RAP and related proteins. They believe that they will be able to target diseased tissues specifically using these technologies. Raptor Corp.'s strategy includes acquiring or in-licensing and developing novel product candidates that target large pharmaceutical markets, which can be rapidly commercialized.